Coherus BioSciences Files 8-K on Financials
Ticker: CHRS · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1512762
Sentiment: neutral
Topics: financial-results, operations, sec-filing
Related Tickers: CHRS
TL;DR
CHRS dropped an 8-K on March 13th detailing financials - check it out.
AI Summary
On March 13, 2024, Coherus BioSciences, Inc. filed an 8-K report detailing its financial results and operations. The filing includes information on the company's financial condition and results of operations, as well as financial statements and exhibits. Specific financial figures and operational details are provided within the document.
Why It Matters
This filing provides investors with crucial updates on Coherus BioSciences' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Registrant
- March 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 333 Twin Dolphin Drive, Suite 600 (address) — Principal executive offices
- Redwood City, CA 94065 (address) — Principal executive offices
FAQ
What specific financial information is disclosed in this 8-K filing?
The filing pertains to the 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', indicating a disclosure of the company's financial performance and condition.
When was the earliest event reported in this filing?
The earliest event reported is dated March 13, 2024.
What is the principal executive office address for Coherus BioSciences, Inc.?
The principal executive offices are located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This Current Report is filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for Coherus BioSciences, Inc.?
The Standard Industrial Classification (SIC) code for Coherus BioSciences, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-13 16:16:56
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
Filing Documents
- chrs-20240313x8k.htm (8-K) — 39KB
- chrs-20240313xex99d1.htm (EX-99.1) — 314KB
- chrs-20240313xex99d1001.jpg (GRAPHIC) — 7KB
- 0001558370-24-003110.txt ( ) — 509KB
- chrs-20240313.xsd (EX-101.SCH) — 4KB
- chrs-20240313_def.xml (EX-101.DEF) — 3KB
- chrs-20240313_lab.xml (EX-101.LAB) — 16KB
- chrs-20240313_pre.xml (EX-101.PRE) — 10KB
- chrs-20240313x8k_htm.xml (XML) — 5KB
02
Item 2.02 Results of Operations and Financial Conditions On March 13, 2024, Coherus BioSciences, Inc. (the "Company") issued a press release regarding its financial results for the fiscal year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K. This information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release dated March 13, 2024 . 104 Cover page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 13, 2024 COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: Chief Executive Officer